1. Scrip
  2. >>Business
  3. >>Deals

Merck KGaA Cancer Deal-Making Spree Continues With PDS Tie-Up

Licenses Promising Candidate For $5m Upfront

 
• By Kevin Grogan

PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.

Merck KGaA Darmstadt
• Source: Merck KGaA

Merck KGaA has continued its run of dealmaking in the oncology field by licensing out its tumor-targeting interleukin-12 fusion protein M924 to PDS Biotechnology Corporation.

The German group will receive $5m upfront, up to $11m in development and regulatory payments and $105m in commercial milestones, plus a 10% royalty on future sales of M9241. Merck...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business